» Articles » PMID: 4737028

Serum Complement in Chronic Liver Disease

Overview
Journal Gut
Specialty Gastroenterology
Date 1973 Jun 1
PMID 4737028
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Total serum haemolytic complement activity (CH(50)) and the serum concentrations of both the third and fourth components of the complement system (C3 and C4) have been measured in 29 control subjects, 92 patients with chronic hepatocellular disease, and eight patients with large duct biliary tract obstruction. The mean C4 concentration was reduced in all types of chronic liver disease studied. However, the mean CH(50) and C3 values were increased in compensated primary biliary cirrhosis, were relatively normal in non-cirrhotic chronic active hepatitis, and were decreased in cryptogenic cirrhosis, particularly when ascites was present. There was a significant correlation between CH(50) and C3 in patients with chronic liver disease but no correlation between CH(50) and C4 or between C3 and C4. Raised values for CH(50) and C3 in primary biliary cirrhosis may be due at least in part to concomitant cholestasis since these values tend to be raised in patients with large duct biliary tract obstruction. Although primary biliary cirrhosis, chronic active hepatitis, and cryptogenic cirrhosis are considered to be part of a spectrum of chronic liver disease associated with disturbed immunity, the results of this study emphasize that there are clearly definable differences between these diseases in terms of the pattern of changes in serum complement.

Citing Articles

Chronic Liver Disease: A Mimic of Systemic Lupus Erythematosus.

Verma G, Kanuru S Cureus. 2021; 13(7):e16765.

PMID: 34476138 PMC: 8403495. DOI: 10.7759/cureus.16765.


"Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.

Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A Front Oncol. 2021; 10:627701.

PMID: 33718121 PMC: 7943925. DOI: 10.3389/fonc.2020.627701.


Roles of the complement system in alcohol-induced liver disease.

Zhou Y, Yuan G, Zhong F, He S Clin Mol Hepatol. 2020; 26(4):677-685.

PMID: 33053939 PMC: 7641541. DOI: 10.3350/cmh.2020.0094.


Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Bedi S, Garcia E, Jeyarajah E, Shalaurova I, Perez-Matos M, Jiang Z J Clin Med. 2020; 9(9).

PMID: 32927635 PMC: 7564541. DOI: 10.3390/jcm9092915.


Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection.

Lamontagne A, Long R, Comunale M, Hafner J, Rodemich-Betesh L, Wang M PLoS One. 2013; 8(6):e64992.

PMID: 23750224 PMC: 3672197. DOI: 10.1371/journal.pone.0064992.


References
1.
Wilson C, Dixon F . Antigen quantitation in experimental immune complex glomerulonephritis. I. Acute serum sickness. J Immunol. 1970; 105(2):279-90. View

2.
PETERS D, Martin A, Weinstein A, Cameron J, BARRATT T, Ogg C . Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol. 1972; 11(3):311-20. PMC: 1553661. View

3.
WEST C, NORTHWAY J, Davis N . SERUM LEVELS OF BETA-1C GLOBULIN, A COMPLEMENT COMPONENT, IN THE NEPHRITIDES, LIPOID NEPHROSIS, AND OTHER CONDITIONS. J Clin Invest. 1964; 43:1507-17. PMC: 441951. DOI: 10.1172/JCI105027. View

4.
Alper C, Johnson A, Birtch A, MOORE F . Human C'3: evidence for the liver as the primary site of synthesis. Science. 1969; 163(3864):286-8. DOI: 10.1126/science.163.3864.286. View

5.
Cooper N, MULLER-EBERHARD H . The reaction mechanism of human C5 in immune hemolysis. J Exp Med. 1970; 132(4):775-93. PMC: 2138854. DOI: 10.1084/jem.132.4.775. View